光制御可能なNOドナーによる勃起不全治療の新規アプローチ

DOI Web Site

書誌事項

タイトル別名
  • A Novel Approach to Treating Erectile Dysfunction with a Light-Controlled Nitric Oxide Donor

抄録

<p>Erection is initiated by the production and release of nitric oxide (NO) via NO synthase upon sexual stimulation. NO relaxes the penile corpus cavernosum smooth muscle, which increases the inflow of blood into the penile corpus cavernosum and compresses the veins, thereby preventing blood loss. This increases the intracavernous pressure in the penile corpus cavernosum to induce erection. Phosphodiesterase 5 (PDE5) inhibitors, which target the NO/cyclic guanosine monophosphate (cGMP) pathway, are currently used to treat erectile dysfunction (ED). PDE5 inhibitors are useful drugs in the general population with ED; however, these inhibitors are not necessarily useful for ED due to diabetes complications or neurogenic conditions after radical prostatectomy. One reason for this low effectiveness is inadequate production of NO in these conditions. Therefore, NO replacement may be an effective ED treatment, but it has been difficult to achieve to date due to systemic side effects.</p><p>To overcome this limitation, we focused on the development of light-controlled NO donors, which can produce NO in response to light, thus producing NO only in localized, light-exposed areas. Light-controlled NO donors can also control the onset and end of drug effects because they can produce NO only for the duration of light exposure. We modified the compound and recently succeeded in developing a red light-responsive NO donor termed "NORD-1" with high tissue permeability.</p><p>In this symposium, we introduce the results of an in vivo study on the enhancement of erectile response with NORD-1 and the effectiveness of the ED model.</p>

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ